---
document_datetime: 2025-09-12 11:08:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/velsipity-epar-all-authorised-presentations_en.pdf
document_name: velsipity-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6717197
conversion_datetime: 2025-12-21 19:05:46.564257
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number                                     | (Invented) name               | Strength       | Pharmaceutical Form                                      | Route of Administration    | Immediate Packaging                                                   | Pack size                        |
|----------------------------------------------------|-------------------------------|----------------|----------------------------------------------------------|----------------------------|-----------------------------------------------------------------------|----------------------------------|
| EU/1/23/1790/001 EU/1/23/1790/002 EU/1/23/1790/003 | VELSIPITY VELSIPITY VELSIPITY | 2 mg 2 mg 2 mg | Film-coated tablet Film-coated tablet Film-coated tablet | Oral use Oral use Oral use | blister (alu/OPA/HDPE/LDPE) blister (alu/OPA/HDPE/LDPE) bottle (HDPE) | 28 tablets 98 tablets 30 tablets |